Register

Company Profile

Sourcing Inquiry Logo ImmunoQure AG

ImmunoQure AG

Regions
Europe
Countries
Germany, Switzerland
Size
n.e.
Specialty
Service category
Pre-clinical development and testing, pre-clinical CRO
Content posted and uploaded by users. Want to add your company?
Your company? Get access to this profile.

Key services

Services

ImmunoQure is focused on developing multiple pre-IND programs in parallel and entering into partnerships with pharmaceutical companies for the further clinical development of these products.

 

IQ001

A cytokine that has been validated in the innate immune system and that is a key regulator of human autoimmune diseases. Antibody panels have been generated, characterized and in vitro mechanism of action studies have been completed.

 

IQ002

A cytokine that has been validated in the innate immune system and that is a key regulator of human autoimmune diseases. Antibody panels have been generated, characterized. In vitro mechanism of action  and in vivo efficacy studies have been completed.

 

IQ003

A cytokine that has been validated as a key regulator of discrete cytokine networks that have been validated clinically and commercially in multiple human autoimmune diseases. Antibody panels have been generated and characterized.

 

Science

 

ImmunoQure AG is focusing on the research and development of human antibodies for the treatment of inflammatory and autoimmune diseases.

Through our unique access to special patient populations, we are able to identify patients that harbor antibodies against key proteins that are involved in preventing many common human diseases.

Our technology platform allows us to rescue desirable antibodies from these patients and generate novel drug candidates with exceptional speed.

ImmunoQure maintains collaborations with leading academic centers in Europe that include specialized clinical institutions, translational medicine and research centers of excellence, and provide us with the ability to access the most relevant patient populations and disease model systems.

Our approach offers scientific and commercial advantages:

  • Clinical symptom-driven target selection
  • Parallel identification of target and human optimized antibody drug candidate
  • Patient disease profiles indicate antibodies are safe and efficacious 
  • Rapid identification of IND-track drug candidates
  • Multiple parallel drug & target screening programs

You might be also interested in

Sourcing this company's services?

Send inquiry anonymously »

Or add this Company to
Sourcing cart